Background. Roux-en-Y gastric bypass (RYGB) is considered an effective and well-tolerated surgical procedure. In this retrospective study, we critically assessed efficacy and negative personal experiences (NPEs) after RYGB with a self-administered questionnaire (SAQ). Methods. This questionnaire study included 404 patients who had undergone RYGB. Analysis was performed using data from medical records, referral letters, and SAQs at an average of 33？months after procedure. We evaluated the occurrence of hypertension, CPEP use and type 2 diabetes mellitus (T2DM), the amount of excess weight loss, degree of satisfaction and negative personal experiences (NPEs) related to the procedure, and adherence to a dedicated life style program and (non)attendance to followup. consults after surgery. Results. 42.3% of all SAQs were evaluable for analysis. T2DM remained similar, while hypertension and continuous positive airway pressure (CPAP) use decreased significantly; excess weight loss of ≥40% was reported in 69% and of <40% in 19%, a significant improvement. Absolute weight gain was reported in 10.5%, fatigue in 44.4%, dysphagia in 11.6%, and other NPEs in 7.6%. Dissatisfaction over weight loss was reported in 9.4%. Mean number of follow-up visits was 9.6 per respondent, while nonattendance of any follow-up visit consults occurred in 1.8%. Conclusions. The use of post-RYGB SAQs provided evaluable data in 42.3%. Treatment failure after RYGB appears to be relevant, encouraging the use of SAQ studies in large cohorts. 1. Introduction Morbid obesity is defined as a chronic condition for which consistent and durable changes of lifestyle are required. Improvement of life style remains critical in any treatment strategy, be it the medical or the surgical approach. In addition, multidisciplinary combined intervention programs for improving life style are mandatory according to international consensus [1]. The Roux-en-Y gastric bypass (RYGB) procedure has emerged as an effective treatment for morbid obesity, in particular for patients with metabolic syndrome and/or type 2 diabetes mellitus (T2DM), obstructive sleep apnea, and hypertension [2–6]. It has also been shown clearly that RYGB is both clinically beneficial and cost effective in the long run [2, 6]. The efficacy of bariatric surgery stems from long-lasting effects leading to a lower obesity-related morbidity and to a significant reduction of mortality [7]. However, weight regain after bariatric surgery diminishes the beneficial effects of surgical interventions as it may lead to recurrence of metabolic consequences
References
[1]
C. M. Apovian, S. Cummings, W. Anderson et al., “Best practice updates for multidisciplinary care in weight loss surgery,” Obesity, vol. 17, no. 5, pp. 871–879, 2009.
[2]
W. J. Pories, M. S. Swanson, K. G. MacDonald et al., “Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus,” Annals of Surgery, vol. 222, no. 3, pp. 339–352, 1995.
[3]
W. J. Pories, “The IDF statement: a big and long-awaited step for our diabetic patients,” Obesity Surgery, vol. 21, pp. 1487–1489, 2011.
[4]
C. K. Huang, A. Shabbir, C. H. Lo, et al., “Laparoscopic Roux-en-Y gastric bypass for the treatment of type II diabetes mellitus in Chinese patients with body mass index of 25–35,” Obesity Surgery, vol. 21, no. 9, pp. 1344–1349, 2011.
[5]
H. Buchwald, R. Estok, K. Fahrbach et al., “Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis,” American Journal of Medicine, vol. 122, no. 3, pp. 248.e5–256.e5, 2009.
[6]
C. D. Sj？str？m, M. Peltonen, H. Wedel, et al., “Differentiated long-term effects of intentional weight loss on diabetes and hypertension,” Hypertension, vol. 36, pp. 20–25, 2000.
[7]
L. Sj？str？m, K. Narbro, C. D. Sj？str？m, et al., “Effects of bariatric surgery on mortality in Swedish obese patients,” The New England Journal of Medicine, vol. 357, pp. 741–752, 2007.
[8]
M. Shah, V. Simha, and A. Garg, “Review: long-term impact of bariatric surgery on body weight, comorbidities, and nutritional status,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 11, pp. 4223–4231, 2006.
[9]
H. J. Sugerman, L. G. Wolfe, D. A. Sica, et al., “Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss,” Annals of Surgery, vol. 237, no. 6, pp. 751–758, 2003.
[10]
C. D. Sj？str？m, M. Peltonen, H. Wedel, and L. Sj？str？m, “Differentiated long-term effects of intentional weight loss on diabetes and hypertension,” Hypertension, vol. 36, no. 1, pp. 20–25, 2000.
[11]
J. Pinkney and D. Kerrigan, “Current status of bariatric surgery in the treatment of type 2 diabetes,” Obesity Reviews, vol. 5, no. 1, pp. 69–78, 2004.
[12]
E. M. H. Mathus-Vliegen, “Nutrition and health—ideal body weight unrealistic; health benefit by moderate sustained weight loss,” Nederlands Tijdschrift voor Geneeskunde, vol. 147, no. 24, pp. 1168–1172, 2003.
[13]
NAASO, The Practical Guide to the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults, NAASO, Silver Spring, Md, USA, 2008.
[14]
National Institutes of Health, National Heart, Lung, and Blood Institute, “Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. National Institutes of Health, National Heart, Lung, and Blood Institute,” Obesity Research, vol. 6, no. 2, pp. S53–S54, 1998.
[15]
M. Fried, V. Hainer, A. Basdevant, et al., “Inter-disciplinary European guidelines on surgery of severe obesity,” International Journal of Obesity (London), vol. 31, pp. 569–577, 2007.
[16]
A. L. Holbrook, J. A. Krosnick, and A. Pfent, “The causes and consequences of response rates in surveys by the news media and government contractor survey research firms,” in Advances in Telephone Survey Methodology, John Wiley & Sons, Hoboken, NJ, USA, 2007.
[17]
A. G. Vargas-Ruiz, G. Hernández-Rivera, and M. F. Herrera, “Prevalence of iron, folate, and vitamin B12 deficiency anemia after laparoscopic Roux-en-Y gastric bypass,” Obesity Surgery, vol. 18, no. 3, pp. 288–293, 2008.
[18]
M. Shah, V. Simha, and A. Garg, “Review: long-term impact of bariatric surgery on body weight, comorbidities, and nutritional status,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 11, pp. 4223–4231, 2006.
[19]
G. M. Campos, C. Rabl, K. Mulligan, et al., “Factors associated with weight loss after gastric bypass,” Archives of Surgery, vol. 143, no. 9, pp. 877–884, 2008.
[20]
M. DiGiorgi, A. Daud, W. B. Inabnet et al., “Markers of bone and calcium metabolism following gastric bypass and laparoscopic adjustable gastric banding,” Obesity Surgery, vol. 18, no. 9, pp. 1144–1148, 2008.
[21]
M. Bose, B. Oliván, J. Teixeira, F. X. Pi-Sunyer, and B. Laferrère, “Do incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: what are the evidence?” Obesity Surgery, vol. 19, no. 2, pp. 217–229, 2009.
[22]
J. Ybarra, E. Bobbioni-Harsch, G. Chassot et al., “Persistent correlation of ghrelin plasma levels with body mass index both in stable weight conditions and during gastric-bypass-induced weight loss,” Obesity Surgery, vol. 19, no. 3, pp. 327–331, 2009.
[23]
N. Pérez-Romero, A. Serra, M. L. Granada et al., “Effects of two variants of Roux-en-Y gastric bypass on metabolism behaviour: focus on plasma ghrelin concentrations over a 2-year follow-up,” Obesity Surgery, vol. 20, no. 5, pp. 600–609, 2010.
[24]
C. M. Borg, C. W. L. Roux, M. A. Ghatei, S. R. Bloom, and A. G. Patel, “Biliopancreatic diversion in rats is associated with intestinal hypertrophy and with increased GLP-1, GLP-2 and PYY levels,” Obesity Surgery, vol. 17, no. 9, pp. 1193–1198, 2007.
[25]
C. W. Le Roux, C. Borg, K. Wallis et al., “Gut hypertrophy after gastric bypass is associated with increased glucagon-like peptide 2 and intestinal crypt cell proliferation,” Annals of Surgery, vol. 252, no. 1, pp. 50–56, 2010.
[26]
N. Scopinaro, G. F. Adami, F. S. Papadia et al., “Effects of biliopanceratic diversion on type 2 diabetes in patients with BMI 25 to 35,” Annals of Surgery, vol. 253, no. 4, pp. 699–703, 2011.
[27]
Y. Martínez, M. D. Ruiz-López, and R. Giménez, “Does bariatric surgery improve the patient's quality of life?” Nutrición Hospitalaria, vol. 25, no. 6, pp. 925–930, 2010.
[28]
S. E. Overs, R. A. Freeman, N. Zarshenas, et al., “Food tolerance and gastrointestinal quality of life following three bariatric procedures: adjustable gastric banding, Roux-en-Y gastric bypass, and sleeve gastrectomy,” Obesity Surgery, no. 4, pp. 536–543, 2012.
[29]
H. O. Lier, E. Biringer, O. Hove, et al., “Quality of life among patients undergoing bariatric surgery: associations with mental health- A 1 year follow-up study of bariatric surgery patients,” Health and Quality of Life Outcomes, vol. 9, article 79, 2011.
